The sedation success rate of remimazolam is non-inferior to that of propofol, and patients who receive remimazolam for hysteroscopy exhibit lower incidences of hypotension, hypoxemia, and injection pain than patients who receive propofol.
Abstract
Procedural sedation is widely used to improve patient tolerability and satisfaction and minimize complications. Propofol is the most commonly used agent in procedural sedation, but its use is associated with a number of adverse effects. Remimazolam, which has a different mechanism of action compared to propofol, is a short-acting GABA-A receptor agonist. It is being increasingly used in procedural sedation. This meta-analysis aims to clarify the efficacy and safety of remimazolam versus propofol for procedural sedation in hysteroscopic surgery. We systematically searched studies published in PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials from the inception of the databases to February 28, 2025, for randomized controlled trials (RCTs) comparing the effect of remimazolam and propofol in procedural sedation for hysteroscopic surgery. Seven RCTs (n = 664 patients) met our inclusion criteria. The pooled results showed that remimazolam significantly reduced the risk of injection pain, hypoxemia, and hypotension (all P < 0.0001) in hysteroscopic surgery, with a sedation success rate comparable to that of propofol (P = 0.05). There were no significant differences in the risks of postoperative dizziness, postoperative nausea and vomiting (PONV), or bradycardia. Findings from sensitivity analyses suggested a potentially higher risk of body movement with remimazolam. We conclude that the sedation success rate of remimazolam is non-inferior to that of propofol, and patients who receive remimazolam for hysteroscopy exhibit lower incidences of hypotension, hypoxemia, and injection pain than patients who receive propofol. Therefore, remimazolam represents a safer alternative to propofol for procedural sedation in hysteroscopic procedures, with a distinct safety profile. Nevertheless, its risk-benefit profile should be carefully evaluated in clinical practice.
BACKGROUND
Remimazolam is a novel ultra-short-acting intravenous benzodiazepine, while sevoflurane is a widely used inhalational anaesthetic for general anaesthesia (GA). Both agents are associated with risks of haemodynamic instability and postoperative nausea and vomiting (PONV), which can affect patient safety and r...
L. Takayama, Kevlin de Souza, David Abraham Batista da Hora et al.· European Journal of Anaesthe...· 0 citations
Despite the growing interest in remifentanil for endoscopic procedures, available data are conflicting. Objective. To evaluate efficacy and safety of remifentanil and fentanyl for analgesia in adults undergoing endoscopic procedures. Material and methods. Nine biomedical databases were screened regarding randomized con...
N. Barkovskaya, E. Shifman, D. Protsenko et al.· Russian Journal of Anesthesi...· 0 citations
This study aimed to explore the efficacy and safety of remimazolam vs. propofol for sedation during video laryngoscopy in cervical spondylosis patients with suspected difficult laryngoscopy.
In this single-center, prospective, randomized controlled study, 85 patients with Modified Mallampati class III or I...
Bin Zhang, Jiao Li, Mingya Wang et al.· European Journal of Medical...· 0 citations
Primary efficacy outcomes demonstrated statistically insignificant differences, although robust evidence indicates intranasal dexmedetomidine is highly superior for pediatric behavioral recovery, although robust evidence indicates midazolam maintains a practical edge strictly for rapid onset.
Ahmad M.Alridahie, Saleh K.Almasoud, Ammar K.Alhajjaj et al.· Annals of Middle Eastern Med...· 0 citations
Preliminary findings indicate that oliceridine reduces the risks of respiratory depression and PONV compared with sufentanil, while analgesic efficacy and hemodynamic stability were comparable in Chinese adults.
Munder Lateiresh, Ayham Qatza, E. Elkoury et al.· European Journal of Clinical...· 0 citations